for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CASI Pharmaceuticals Inc

CASI.OQ

Latest Trade

3.25USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.75

 - 

5.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.25
Open
--
Volume
--
3M AVG Volume
4.00
Today's High
--
Today's Low
--
52 Week High
5.98
52 Week Low
2.75
Shares Out (MIL)
95.72
Market Cap (MIL)
324.48
Forward P/E
-8.84
Dividend (Yield %)
--

Next Event

Q3 2019 CASI Pharmaceuticals Inc Earnings Release

Latest Developments

More

Casi Pharmaceuticals Inc - Board Unanimously Voted To Appoint (Wei) Larry Zhang As President

Casi Pharmaceuticals Inc - QTRLY Loss Per Share $0.16

CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize Anti-CD19 T-cell Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Industry

Biotechnology & Drugs

Contact Info

9620 Medical Center Dr Ste 300

+1.240.8642600

http://www.casipharmaceuticals.com/

Executive Leadership

Wei-Wu He

Executive Chairman of the Board, Chief Executive Officer

Wei Zhang

President, President of CASI China

George Chi

Chief Financial Officer

Cynthia Wong Hu

Chief Operating Officer, General Counsel, Secretary

Sara B. Capitelli

Vice President - Finance, Principal Accounting Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.170

2017

-0.180

2018

-0.320

2019(E)

-0.383
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.68
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.15
Return on Equity (TTM)
-40.46

Latest News

BRIEF-CASI Pharmaceuticals Reports Q1 Loss Per Share Of $0.05

* CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL AND BUSINESS RESULTS

BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26

* CASI PHARMACEUTICALS - RECEIPT OF LETTER FROM CENTER FOR DRUG EVALUATION FOR INJECTION SCHEDULED FOR REVIEW BY ADVISORY COMMITTEE

BRIEF-CASI Pharmaceuticals Q4 Loss Per Share $0.08

* CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-CASI Pharmaceuticals Announces $50 Million Private Placement

* CASI PHARMACEUTICALS ANNOUNCES $50 MILLION PRIVATE PLACEMENT TO PREPARE COMPANY FOR COMMERCIALIZATION IN CHINA

BRIEF-Casi Pharmaceuticals Enters Into A Common Stock Sales Agreement With H.C. Wainwright & Co

* CASI PHARMACEUTICALS INC SAYS ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO LLC - SEC FILING

BRIEF-CASI Pharma Board Approves Appointment Of Wei-Wu He As Executive Chairman

* CASI PHARMACEUTICALS - ON FEB 7, BOARD APPROVED APPOINTMENT OF WEI-WU HE, CURRENT CHAIRMAN OF BOARD, AS EXECUTIVE CHAIRMAN - SEC FILING Source text: (http://bit.ly/2EUtR7g) Further company coverage:

BRIEF-Casi Pharmaceuticals Files For Stock Shelf Of Upto $100 Million

* CASI PHARMACEUTICALS INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text: [http://bit.ly/2zaieHQ] Further company coverage:

BRIEF-Casi pharmaceuticals Q3 loss per share $0.03

* Casi Pharmaceuticals reports third quarter 2017 financial results

BRIEF-CASI PHARMACEUTICALS ANNOUNCES $23.8 MLN REGISTERED DIRECT OFFERING

* CASI PHARMACEUTICALS ANNOUNCES $23.8 MILLION REGISTERED DIRECT OFFERING LED BY EXISTING SHAREHOLDERS

BRIEF-CASI provides pipeline development update

* CASI Pharmaceuticals Inc- CFDA has granted priority review for co's import drug registration clinical trial application for EVOMELA for injection Source text for Eikon: Further company coverage:

BRIEF-Casi Pharmaceuticals reports Q2 loss per share $0.04

* Casi Pharmaceuticals reports second quarter 2017 financial results

BRIEF-Casi Pharmaceuticals reports Q1 loss per share $0.03

* Casi Pharmaceuticals reports first quarter 2017 financial results

BRIEF-CASI Pharmaceuticals reports on enrollment status of ENMD-2076 phase 2 study in triple-negative breast cancer

* Says decision has been reached to stop further patient enrollment in its phase 2, open-label study of enmd-2076

BRIEF-Casi Pharmaceuticals reports Q4 loss per share $0.05

* CASI Pharmaceuticals reports 2016 fourth quarter and full year financial results

BRIEF-Casi Pharmaceuticals reports third quarter 2016 results

* Casi Pharmaceuticals reports third quarter 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up